Avutometinib

DRUG12 trials

Sponsors

Emory University, Memorial Sloan Kettering Cancer Center, Verastem, Inc., University of Utah, M.D. Anderson Cancer Center

Conditions

Advanced Colorectal CancerAdvanced Lung AdenocarcinomaAvutometinibBrain MetastasesCNS Tumor, AdultCNS Tumor, ChildhoodCNS TumorsCancer of the Pancreas

Early Phase 1

Identification of Treatment Concentrations of Defactinib or VS-6766 for the Treatment of Patients With Glioblastoma

Active, not recruitingNCT05798507

Emory UniversityGlioblastoma, Recurrent Glioblastoma

Start: 2023-07-28End: 2027-12-03Updated: 2025-12-15

Phase 1

A Study of Avutometinib for People With Solid Tumor Cancers

Active, not recruitingNCT06104488

Memorial Sloan Kettering Cancer CenterCentral Nervous System Tumor, CNS Tumor, Adult, CNS Tumor, Childhood +12

Start: 2023-10-20End: 2029-10-20Updated: 2026-06-15

Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous Melanoma

RecruitingNCT06194929

University of UtahBrain Metastases, Cutaneous Melanoma

Start: 2024-03-20End: 2030-01-15Target: 33Updated: 2025-12-03

5G-RUBY: Avutometinib and Defactinib in Malignant Brain Tumours

RecruitingNCT06630260

Institute of Cancer Research, United KingdomDiffuse Hemispheric Glioma, H3 G34-Mutant, Glioblastoma Multiforme (GBM), Glioblastoma Multiform (Grade IV Astrocytoma) +1

Start: 2024-11-15End: 2030-09-30Target: 182Updated: 2026-01-21

Phase Ib Study of Avutometinib, Defactinib, and Everolimus in RAS Pathway Mutant Endometrial Cancer

RecruitingNCT07318324

M.D. Anderson Cancer CenterAvutometinib, Endometrial, Phase IB +1

Start: 2026-05-13End: 2030-08-01Target: 31Updated: 2026-06-29

Phase 2

A Study of Avutometinib and Defactinib in People With Thyroid Cancer

RecruitingNCT06007924

Memorial Sloan Kettering Cancer CenterThyroid Cancer

Start: 2023-08-16End: 2027-08-16Target: 30Updated: 2026-06-22

Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-Refractory Advanced Colorectal Cancer

RecruitingNCT06369259

M.D. Anderson Cancer CenterAdvanced Colorectal Cancer

Start: 2025-02-24End: 2029-02-01Target: 33Updated: 2026-09-04

A Study of Avutometinib, Defactinib, and Letrozole in People With Low-Grade Serous Ovarian Cancer

RecruitingNCT06394804

Memorial Sloan Kettering Cancer CenterLow-Grade Serous Ovarian Cancer

Start: 2024-04-29End: 2027-04-01Target: 20Updated: 2026-07-20

Avutometinib and Defactinib in Diffuse Gastric Cancer

RecruitingNCT06487221

Ryan H. Moy, MD, PhDGastric Cancer, Stomach Cancer

Start: 2024-10-28End: 2029-05-30Target: 27Updated: 2025-11-04

Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung Cancer

RecruitingNCT06495125

Emory UniversityAdvanced Lung Adenocarcinoma, Refractory Lung Adenocarcinoma, Stage III Lung Cancer AJCC v8 +1

Start: 2024-07-31End: 2029-09-17Target: 50Updated: 2026-04-06

Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma

RecruitingNCT07126158

Washington University School of MedicineCancer of the Pancreas, Pancreas Cancer, Pancreatic Adenocarcinoma +1

Start: 2026-04-10End: 2030-04-30Target: 36Updated: 2026-04-15

Phase 3

A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer

RecruitingNCT06072781

Verastem, Inc.Low Grade Serous Ovarian Cancer

Start: 2024-03-18End: 2031-02-09Target: 270Updated: 2026-08-14

Related Papers

Abstract 2232: Investigating the combined inhibition of RAF, MEK, and FAK in melanoma molecular subtypes.

Cancer Research2026-04-03

Window of opportunity study measuring defactinib and avutometinib delivery in glioblastomas.

2026-03-06

Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201

Journal of Clinical Oncology2025-07-1112 citations

Abstract 6368: Correlative preclinical studies to elucidate mechanisms of synergy of the combination of the RAF/MEK clamp avutometinib and the FAK inhibitor defactinib in low grade serous ovarian cancer

Cancer Research2025-04-21

Abstract 4393: RAF/MEK clamp avutometinib combined with a pan-RAF inhibitor induces nearly complete MAPK pathway inhibition with deep tumor regressions in NRAS or BRAF class III mutant models

Cancer Research2025-04-21

Phase 2 trial of defactinib in combination with avutometinib in patients with advanced diffuse-type gastric cancer.

Journal of Clinical Oncology2025-01-273 citations

The combination of avutometinib and defactinib in treating recurrent low-grade serous ovarian cancer: a plain language summary of the Phase II clinical trial ENGOT-OV60/GOG-3052/RAMP 201

2025-01-01

The combination of avutometinib and defactinib in treating recurrent low-grade serous ovarian cancer: a plain language summary of the Phase II clinical trial ENGOT-OV60/GOG-3052/RAMP 201

OPAL (Open@LaTrobe) (La Trobe University)2025-01-01

GOG-3097/ENGOT-ov81/GTG-UK/RAMP 301: a phase 3, randomized trial evaluating avutometinib plus defactinib compared with investigator’s choice of treatment in patients with recurrent low grade serous ovarian cancer

International Journal of Gynecological Cancer2024-10-0715 citations